SAP155-mediated splicing of FUSE-binding protein-interacting repressor serves as a molecular switch for c-myc gene expression

Molecular Cancer Research

Volumn 10, Issue 6, 2012, Pages 787-799

  Matsushita, Kazuyuki ^a   Kajiwara, Toshiko ^a   Tamura, Mai ^a   Satoh, Mamoru ^a   Tanaka, Nobuko ^a   Tomonaga, Takeshi ^c   Matsubara, Hisahiro ^b   Shimada, Hideaki ^d   Yoshimoto, Rei ^f   Ito, Akihiro ^f   Kubo, Shuji ^g   Natsume, Tohru ^e   Levens, David ^h   Yoshida, Minoru ^f   Nomura, Fumio ^a  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^d TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

^e NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^f RIKEN   (Japan)

^g HYOGO COLLEGE OF MEDICINE   (Japan)

^h NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; MESSENGER RNA; PROTEIN FAR UPSTREAM ELEMENT BINDING PROTEIN INTERACTING REPRESSOR; REPRESSOR PROTEIN; SAP 155; SMALL NUCLEAR RIBONUCLEOPROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE COURSE; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; HELA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN MODIFICATION; REPRESSOR GENE; RNA SPLICING; UPREGULATION;

ALTERNATIVE SPLICING; AMINO ACID SEQUENCE; BASE SEQUENCE; BLOTTING, WESTERN; COLORECTAL NEOPLASMS; EXONS; HCT116 CELLS; HEK293 CELLS; HELA CELLS; HUMANS; INTRONS; MOLECULAR SEQUENCE DATA; MUTATION; PHOSPHOPROTEINS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MYC; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBONUCLEOPROTEIN, U2 SMALL NUCLEAR; RNA INTERFERENCE; RNA PRECURSORS; RNA-BINDING PROTEINS; TRANSCRIPTION, GENETIC;

EID: 84862575914     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-11-0462     Document Type: Article

References (39)

1. Avigan MI, Strober B, Levens D. A far upstream element stimulates c-myc expression in undifferentiated leukemia cells. J Biol Chem 1990;265:18538-45.
2. Duncan R, Bazar L, Michelotti G, Tomonaga T, Krutzsch H, Avigan M, et al. A sequence-specific, single-strand binding protein activates the far upstream element of c-myc and defines a new DNA-binding motif. Genes Dev 1994;8:465-80. (Pubitemid 24071186)
3. Bazar L, Meighen D, Harris V, Duncan R, Levens D, Avigan M. Targeted melting and binding of a DNA regulatory element by a transactivator of c-myc. J Biol Chem 1995;270:8241-8.
4. Michelotti GA, Michelotti EF, Pullner A, Duncan RC, Eick D, Levens D. Multiple single-stranded cis elements are associated with activated chromatin of the human c-myc gene in vivo. Mol Cell Biol 1996;16:2656-69. (Pubitemid 26161269)
5. Liu J, He L, Collins I, Ge H, Libutti D, Li J, et al. The FBP interacting repressor targets TFIIH to inhibit activated transcription. Mol Cell 2000;5:331-41. (Pubitemid 30628091)
6. Liu J, Akoulitchev S, Weber A, Ge H, Chuikov S, Libutti D, et al. Defective interplay of activators and repressors with TFIH in xeroderma pigmentosum. Cell 2001;104:353-63. (Pubitemid 32206456)
7. Matsushita K, Tomonaga T, Shimada H, Shioya A, Higashi M, Matsubara H, et al. An essential role of alternative splicing of c-myc suppressor FIR in carcinogenesis. Cancer Res 2006;66:1409-17. (Pubitemid 43259921)
8. Will CL, Urlaub H, Achsel T, Gentzel M, Wilm M, Lührmann R. Characterization of novel SF3b and 17S U2 snRNP proteins, including a human Prp5p homologue and an SF3b DEAD-box protein. EMBO J 2002;21:4978-88.
9. Spadaccini R, Reidt U, Dybkov O, Will C, Frank R, Stier G, et al. Biochemical and NMR analyses of an SF3b155-p14-U2AF-RNA interaction network involved in branch point definition during pre-mRNA splicing. RNA 2006;12:410-2.
10. Hastings ML, Allemand E, Duelli DM, Myers MP, Krainer AR. Control of pre-mRNA splicing by the general splicing factors PUF60 and U2AF (65). PLoS One 2007;2:e538.
11. Mollet I, Barbosa-Morais NL, Andrade J, Carmo-Fonseca M. Diversity of human U2AF splicing factors. FEBS J 2006;273:4807-16.
12. Corsini L, Hothorn M, Stier G, Rybin V, Scheffzek K, Gibson TJ, et al. Dimerization and protein binding specificity of the U2AF homology motif of the splicing factor Puf60. J Biol Chem 2009;284:630-9.
13. Kaida D, Motoyoshi H, Tashiro E, Nojima T, Hagiwara M, Ishigami K, et al. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat Chem Biol 2007;3:576-83. (Pubitemid 47294395)
14. Kotake Y, Sagane K, Owa T, Mimori-Kiyosue Y, Shimizu H, Uesugi M, et al. Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat Chem Biol 2007;3:570-5. (Pubitemid 47294394)
15. Kimura K, Nozaki N, Enomoto T, Tanaka M, Kikuchi A. Analysis of M phase-specific phosphorylation of DNA topoisomerase II. J Biol Chem 1996;271:21439-45. (Pubitemid 26293008)
16. Page-McCaw PS, Amonlirdviman K, Sharp PA. PUF60: a novel U2AF65-related splicing activity. RNA 1999;5:1548-60.
17. Kristjansdottir K, Wolfgeher D, Lucius N, Angulo DS, Kron SJ. Phosphoprotein profiling by PA-GeLC-MS/MS. J Proteome Res 2008;7:2812-24.
18. Tomonaga T, Matsushita K, Ishibashi M, Nezu M, Shimada H, Ochiai T, et al. Centromere protein His up-regulated in primary human colorectal cancer and its overexpression induces aneuploidy. Cancer Res 2005;65:4683-9. (Pubitemid 40740804)
19. Seimiya M, Tomonaga T, Matsushita K, Sunaga M, Oh-Ishi M, Kodera Y, et al. Identification of novel immunohistochemical tumor markers for primary hepatocellular carcinoma; clathrin heavy chain and formiminotransferase cyclodeaminase. Hepatology 2008;48:519-30.
20. Nishimori T, Tomonaga T, Matsushita K, Oh-Ishi M, Kodera Y, Maeda T, et al. Proteomic analysis of primary esophageal squamous cell carcinoma reveals downregulation of a cell adhesion protein, periplakin. Proteomics 2006;6:1011-8. (Pubitemid 43260225)
21. Natsume T, Yamauchi Y, Nakayama H, Shinkawa T, Yanagida M, Takahashi N, et al. A direct nanoflow liquid chromatography-tandem mass spectrometry system for interaction proteomics. Anal Chem 2002;74:4725-33.
22. Mizushima N, Kuma A, Kobayashi Y, Yamamoto A, Matsubae M, Takao T, et al. Mouse Apg16L, a novel WD-repeat protein, targets to the autophagic isolation membrane with the Apg12-Apg5 conjugate. J Cell Sci 2003;116:1679-88. (Pubitemid 36582155)
23. Yanagida M, Hayano T, Yamauchi Y, Shinkawa T, Natsume T, Isobe T, et al. Human fibrillarin forms a sub-complex with splicing factor 2-associated p32, protein arginine methyltransferases, and tubulins alpha 3 and beta 1 that is independent of its association with preribosomal ribonucleoprotein complexes. J Biol Chem 2004;279:1607-14. (Pubitemid 38084425)
24. Komatsu M, Chiba T, Tatsumi K, Iemura S, Tanida I, Okazaki N, et al. A novel protein-conjugating system for Ufm1, a ubiquitin-fold modifier. EMBO J 2004;23:1977-86. (Pubitemid 38902076)
25. Brosi R, Hauri HP, Krämer A. Separation of splicing factor SF3 into two components and purification of SF3a activity. J Biol Chem 1993;268:17640-6. (Pubitemid 23237012)
26. Das BK, Xia L, Palandjian L, Gozani O, Chyung Y, Reed R. Characterization of a protein complex containing spliceosomal proteins SAPs 49, 130, 145, and 155. Mol Cell Biol 1999;19:6796-802. (Pubitemid 29441863)
27. Kitamura A, Matsushita K, Takiguchi Y, Shimada H, Tomonaga T, Matsubara H, et al. Synergistic effect of non-transmissible Sendai virus vector encoding the c-myc suppressor FUSE-binding protein-interacting repressor plus cisplatin in treatment of malignant pleural mesothelioma. Cancer Sci 2011;102:1366-73.
28. Noubissi FK, Nikiforov MA, Colburn N, Spiegelman VS. Transcriptional regulation of CRD-BP by c-myc: implications for c-myc functions. Genes Cancer 2010;10:1074-82.
29. Noubissi FK, Elcheva I, Bhatia N, Shakoori A, Ougolkov A, Liu J, et al. CRD-BP mediates stabilization of betaTrCP1 and c-myc mRNA in response to beta-catenin signalling. Nature 2006;441:898-901.
30. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011 Sep 11 [Epub ahead of print].
31. Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011 Oct 13;365:1384-95.
32. Cukier CD, Hollingworth D, Martin SR, Kelly G, Díaz-Moreno I, Ramos A. Molecular basis of FIR-mediated c-myc transcriptional control. Nat Struct Mol Biol 2010;17:1058-64.
33. Crichlow GV, Zhou H, Hsiao HH, Frederick KB, Debrosse M, Yang Y, et al. Dimerization of FIR upon FUSE DNA binding suggests a mechanism of c-myc inhibition. EMBO J 2008;27:277-89.
34. Gardina PJ, Clark TA, Shimada B, Staples MK, Yang Q, Veitch J, et al. Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array. BMC Genomics 2006;7:325-35.
35. Furumai R, Uchida K, Komi Y, Yoneyama M, Ishigami K, Watanabe H, et al. Spliceostatin A blocks angiogenesis by inhibiting global gene expression including VEGF. Cancer Sci 2010;101:2483-9.
36. Zorio DA, Bentley DL. The link between mRNA processing and transcription: communication works both ways. Exp Cell Res 2004;296:91-7. (Pubitemid 38543218)
37. Alexander R, Beggs JD. Cross-talk in transcription, splicing and chromatin: who makes the first call? Biochem Soc Trans 2010;38:1251-6.
38. Matsushita K, Tomonaga T, Kajiwara T, Shimada H, Itoga S, Hiwasa T, et al. c-myc suppressor FBP-interacting repressor for cancer diagnosis and therapy. Front Bios 2009;14:3401-8.
39. Hasegawa M, Miura T, Kuzuya K, Inoue A, Won KS, Horinouchi S, et al. Identification of SAP155 as the target of GEX1A (Herboxidiene), an antitumor natural product. ACS Chem Biol 2011;6:229-33.